Evidence map›Paper›PMID 22718398›Full record

ReviewCancer metastasis reviews2012

The faces and friends of RhoGDI2.

Erin M Griner, Dan Theodorescu

Abstract readReview
In one paragraph

Review in Cancer metastasis reviews, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. RhoGDI1 regulates cell-cell junctions in polarized epithelial cells.Frontiers in cell and developmental biology · 2024
    Article
  6. Electrostatic Forces Mediate the Specificity of RHO GTPase-GDI Interactions.International journal of molecular sciences · 2021
    Article
  7. Review
  8. Article
  9. Review
  10. Systematic investigation of biomarker-like role of ARHGDIB in breast cancer.Cancer biomarkers : section A of Disease markers · 2020
    Article
  11. Article
  12. Article
  13. Article
  14. An adventitious interaction of filamin A with RhoGDI2(Tyr153Glu).Biochemical and biophysical research communications · 2016
    Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Erin M GrinerCenter for Cell Signaling and Department of Microbiology, Immunology and Cancer Biology, University of Virginia, Charlottesville, VA 22908, USA.
Dan Theodorescu

Funding

Understanding the RhoGDI2 metastasis suppressor geneR01CA143971 · NCI · UNIVERSITY OF COLORADO DENVER · PI THEODORESCU, DAN · 2010 to 2020
$4.4M
NCI NIH HHS CA143971NCI NIH HHS CA910935NCI NIH HHS R01 CA143971
6 · The paper itself

Abstract

RhoGDI2 is a guanine nucleotide dissociation inhibitor (GDI) specific for the Rho family of small GTPases that plays dual opposite roles in tumor progression, being both a promoter in tissues such as breast and a metastasis suppressor in tissues such as the bladder. Despite a clear role for this protein in modulating the invasive and metastatic process, the mechanisms through which RhoGDI2 executes these functions remain unclear. This review will highlight the current state of our knowledge regarding how RhoGDI2 functions in metastasis with a focus on bladder cancer and will also seek to highlight other potential underappreciated avenues through which this protein may affect cancer cell behavior.

Indexed as

Neoplasm MetastasisAnimalsApoptosisEndothelin-1GTP PhosphohydrolasesHumansProtein Kinase C-alpharho Guanine Nucleotide Dissociation Inhibitor betaUrinary Bladder NeoplasmsEndothelin-1GTP PhosphohydrolasesPRKCA protein, humanProtein Kinase C-alpharho Guanine Nucleotide Dissociation Inhibitor beta

Identifiers

PMID22718398
PMCPMC11207192

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.